Signant Health Acquires Ametris to Combine Wearable Data and eCOA Technology – Image for illustrative purposes only (Image credits: Pexels)
Clinical research has long struggled with fragmented information sources that force sponsors to juggle separate vendors for patient feedback and sensor readings. Signant Health has now acquired Ametris, the company previously known as ActiGraph, to bring those two data streams under one platform. The transaction, whose financial terms remain undisclosed, targets a persistent bottleneck in decentralized and hybrid trial designs where participants contribute information from everyday environments rather than clinic visits.
Why Sponsors Need a Single Evidence Platform
Pharmaceutical companies face mounting pressure from regulators and payers who demand richer, more continuous datasets to support approval and reimbursement decisions. Traditional setups kept subjective reports and objective measurements in isolated systems, creating extra complexity and potential gaps in the overall picture. By combining Signant’s electronic clinical outcome assessment tools with Ametris’s two decades of regulatory-aligned wearable experience, the combined company offers sponsors one workflow instead of multiple disconnected contracts.
Signant already works with more than 600 sponsors and contract research organizations, including every top-20 pharmaceutical firm. The acquisition therefore extends an existing reach while adding specialized sensor capabilities that track physical activity and physiological markers outside controlled settings.
Closing the Gap Between Reported Symptoms and Measured Signals
Patient-reported outcomes capture how individuals feel and function day to day, yet they remain inherently subjective. Wearable sensors, by contrast, record continuous, quantifiable data on movement, sleep, and vital signs. When these two layers sit in separate systems, analysts lose the chance to see how reported symptoms align with actual physiological changes over time. The merged platform is intended to close that divide, especially in central nervous system disorders and other complex conditions where regulators increasingly expect multimodal evidence.
Jeremy Wyatt, who leads Ametris, has pointed out that the combination should speed development of integrated evidence systems and reduce the administrative burden on trial sponsors. Roger Smith, Signant’s chief executive, described the deal as a step toward more unified clinical evidence generation. Both statements underscore a practical goal: fewer handoffs between vendors and a clearer longitudinal record for each participant.
Next Steps in Analytics and Machine Learning
Immediate priorities focus on shared workflows and combined analytics dashboards that let study teams view patient reports and sensor readings side by side. Longer term, the companies intend to explore artificial intelligence and machine learning models that can surface patterns across the two data types. Such models could eventually support composite outcome measures or real-time monitoring, though those applications remain in early planning stages and will require further validation before widespread use.
Regulators have already signaled interest in these capabilities, yet questions persist about how composite endpoints will be qualified and how privacy safeguards will scale with continuous data collection. The acquisition therefore positions the combined firm to participate in those conversations while sponsors test the practical limits of the new technology.
What the Move Signals for Ongoing Research
Decentralized trials continue to expand, and sponsors are looking for ways to maintain data quality without increasing operational complexity. The Signant-Ametris combination illustrates one path forward: a single vendor that can deliver both subjective and objective measures within the same regulatory framework. Whether this model becomes standard practice will depend on how quickly the promised analytics mature and how regulators respond to the richer datasets they produce.
